Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: Results from continuous dose-effect models

European Journal of Clinical Investigation

Volumn 39, Issue 1, 2009, Pages 51-57

  Walter, M A ^a   Schindler, C ^b,c   Christ Crain, M ^a   Muller Brand J ^a   Muller B ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Antithyroid drugs; Carbimazole; Graves' disease; Hyperthyroidism; Radioiodine; Toxic nodular goitre

Indexed keywords

CARBIMAZOLE; IODINE 123; IODINE 131;

ADULT; AGED; ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; EUTHYROIDISM; FEMALE; GRAVES DISEASE; HUMAN; HYPOTHYROIDISM; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; SINGLE DRUG DOSE; TOXIC GOITER;

ANTITHYROID AGENTS; CARBIMAZOLE; GOITER, NODULAR; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; MODELS, BIOLOGICAL; RADIATION DOSAGE; STATISTICS AS TOPIC;

EID: 57649178306     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2008.02061.x     Document Type: Article

References (24)

1. Franklyn JA. The management of hyperthyroidism. N Engl J Med 1994 330 : 1731 8.
2. Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes K et al. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 1999 84 : 1229 33.
3. Walter MA, Christ-Crain M, Schindler C, Müller-Brand J, Müller B. Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur J Nucl Med Mol Imaging 2006 33 : 730 7.
4. Steinbach JJ, Donoghue GD, Goldman JK. Simultaneous treatment of toxic diffuse goiter with I-131 and antithyroid drugs: a prospective study. J Nucl Med 1979 20 : 1263 7.
5. Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedus L. Continuous methimazole therapy and its effect on the cure rate of hyperthyroidism using radioactive iodine: an evaluation by a randomized trial. J Clin Endocrinol Metab 2006 91 : 2946 51.
6. Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 2007 334 : 514 7.
7. Buchanan WW, Koutras DA, Crooks J, Harden RM. A comparison of pretreatment with potassium perchlorate and methylthiouracil on results of 131-I therapy. Br J Radiol 1965 38 : 536 40.
8. Calegaro JU, De Freitas Gomes E, Bae SH, Ulyssea R, Casulari LA. One-year follow-up of Graves' disease treatment by four different protocols of radioiodine administration. Panminerva Med 2000 42 : 241 5.
9. Lind P. Strategies of radioiodine therapy for Graves' disease. Eur J Nucl Med Mol Imaging 2002 29 (Suppl 2 S453 7.
10. Brent GA. Clinical practice. Graves' disease. N Engl J Med 2008 358 : 2594 605.
11. Walter MA, Christ-Crain M, Müller B. Graves' disease. N Engl J Med 2008 359 : 1407 9.
12. Zophel K, Wunderlich G, Gruning T, Koch R, Doge H, Kotzerke J. [Where does subclinical hypothyroidism start? Implications for the definition of the upper reference limit for thyroid stimulating hormone]. Nuklearmedizin 2005 44 : 56 61.
13. Toft AD. Clinical practice. Subclinical hyperthyroidism. N Engl J Med 2001 345 : 512 6.
14. Walter MA, Christ-Crain M, Müller B, Müller-Brand J. Radioiodine uptake and thyroid hormone levels on or off simultaneous carbimazole medication: a prospective paired comparison. Nuklearmedizin 2005 44 : 33 6.
15. Walter MA, Christ-Crain M, Eckard B, Schindler C, Nitzsche EU, Müller-Brand J et al. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. Eur J Clin Invest 2004 34 : 365 70.
16. Bockisch A, Jamitzky T, Derwanz R, Biersack HJ. Optimized dose planning of radioiodine therapy of benign thyroidal diseases. J Nucl Med 1993 34 : 1632 8.
17. Crooks J, Wayne EJ, Robb RA. A clinical method of assessing the results of therapy in thyrotoxicosis. Lancet 1960 1 : 397 401.
18. Marinelli LD. Dosage determination in the use of radioactive isotopes. J Clin Invest 1949 28 : 1271 80.
19. Howarth D, Epstein M, Lan L, Tan P, Booker J. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study. Eur J Nucl Med 2001 28 : 1489 95.
20. Reinhardt MJ, Brink I, Joe AY, Von Mallek D, Ezziddin S, Palmedo H et al. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med Mol Imaging 2002 29 : 1118 24.
21. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab 2003 88 : 978 83.
22. Reiners C, Schneider P. Radioiodine therapy of thyroid autonomy. Eur J Nucl Med Mol Imaging 2002 29 (Suppl 2 S471 8.
23. Sabri O, Zimny M, Schreckenberger M, Reinartz P, Ostwald E, Buell U. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy. Thyroid 1999 9 : 1181 8.
24. 123I. Eur J Nucl Med Mol Imaging 2002 29 : 783 8.